Summary by Moomoo AI
KEYSTONE PHARMACEUTICAL-B (STOCK CODE: 2616) WILL HOLD AN INTERIM GENERAL MEETING ON JANUARY 17, 2024 TO CONSIDER THE PROPOSAL TO GRANT A SHARE OPTION TO THE EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER, DR. YANG JIANXIN. THE SHARE OPTION GRANT IS UNDER THE TERMS OF THE COMPANY'S INITIAL PUBLIC OFFERING EMPLOYEE EQUITY PLAN AND IS RELATED TO THE PERFORMANCE TARGET MILESTONES ACHIEVED BY DR. YANG. The exercise price of the share option is HK$2,350 per share, which is higher than the closing price of the shares on the date of issue and the average closing price of the previous five business days. In addition, the Company will suspend the registration of shares from 12 to 17 January 2024 in preparation for the General Meeting. Shareholders who wish to vote at the General Meeting must submit the Proxy Form by 10 a.m. on 15 January 2024. The Board of Directors of the Company and the independent non-executive directors recommend that shareholders approve the ordinary resolution.